DCCT and EDIC studies in type 1 diabetes: Lessons for diabetic neuropathy regarding metabolic memory and natural history

Current Diabetes Reports

Volumn 10, Issue 4, 2010, Pages 276-282

  Pop Busui, Rodica ^a   Herman, William H ^a   Feldman, Eva L ^a   Low, Phillip A ^b   Martin, Catherine L ^a   Cleary, Patricia A ^c   Waberski, Barbara H ^c   Lachin, John M ^c   Albers, James W ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Cardiovascular autonomic neuropathy; Distal symmetrical polyneuropathy; Glycemic control; Heart rate variability studies; Nerve conduction studies

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT;

AUTONOMIC NEUROPATHY; BLOOD PRESSURE MEASUREMENT; BODY POSTURE; BREATHING PATTERN; CLINICAL TRIAL; DIABETIC NEUROPATHY; DISEASE COURSE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTENSIVE CARE; NERVE CONDUCTION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROLOGIC EXAMINATION; REVIEW; RISK REDUCTION; RR INTERVAL; TREATMENT DURATION; TREATMENT OUTCOME; VALSALVA MANEUVER; AUTONOMIC NERVOUS SYSTEM DISEASES; CARDIOMYOPATHIES; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; FEMALE; MALE; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AUTONOMIC NERVOUS SYSTEM DISEASES; CARDIOMYOPATHIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77956394914     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-010-0120-8     Document Type: Review

References (15)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977-986.
2. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial [no authors listed]. Ann Neurol 1995, 38:869-880.
3. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT) [no authors listed]. Diabetologia 1998, 41:416-423.
4. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort [no authors listed]. Diabetes Care 1999, 22:99-111.
5. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy [no authors listed]. N Engl J Med 2000, 342:381-389.
6. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus [no authors listed]. JAMA 2002, 287:2563-2569.
7. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003, 290:2159-2167.
8. Nathan DM, Cleary PA, Backlund JY, et al.: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
9. Martin CL, Albers J, Herman WH, et al.: Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006, 29:340-344.
10. Pop-Busui R, Low PA, Waberski BH, et al.: Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009, 119:2886-2893. This paper evaluated the effects of prior intensive insulin therapy on the prevalence and incidence of cardiac autonomic neuropathy in former DCCT intensive and conventional therapy subjects 13 to 14 years after DCCT closeout.
11. Albers JW, Herman WH, Pop-Busui R, et al.: Effect of prior intensive insulin treatment during the Diabetes Control And Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions, and Complications (EDIC) Study. Diabetes Care 2010 Feb 11 [Epub ahead of print]. This paper evaluated the impact of former intensive versus conventional insulin treatment on distal symmetrical neuropathy in DCCT intensive and conventional treatment subjects with type 1 diabetes 13 to 14 years after DCCT closeout.
12. Orchard TJ, Forrest KY, Ellis D, et al.: Cumulative glycemic exposure and microvascular complications in insulin-dependent diabetes mellitus. The glycemic threshold revisited. Arch Intern Med 1997, 157:1851-1856.
13. Dyck PJ, Davies JL, Clark VM, et al.: Modeling chronic glycemia exposure variables as correlates and predictors of microvascular complications of diabetes. Diabetes Care 2006, 29:2282-2288.
14. Tesfaye S, Chaturvedi N, Eaton SE, et al.: Vascular risk factors and diabetic neuropathy. N Engl J Med 2005, 352:341-350.
15. White NH, Sun W, Cleary PA, et al.: Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008, 126:1707-1715. This paper examined differences in the persistence of the benefits of intensive therapy on retinopathy 10 years after completion of the DCCT.